About 17 results found for searched term "TGF-β Receptor" (0.337 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1794 | SB431542 | ALK |
| SB-431542 | ||
| SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM). | ||
| M1859 | RepSox (ALK5 Inhibitor II) | ALK |
| RepSox; E-616452; SJN 2511; 616452 | ||
| RepSox (ALK5 Inhibitor II) is a potent and ATP-competitive inhibitor of the TGF-β type I receptor ALK5 (IC50 values are 0.004 and 0.023 μM for ALK5 autophosphorylation and ALK5 binding respectively). | ||
| M2016 | LY364947 | TGF-β Receptor |
| HTS 466284 | ||
| LY364947 is a selective small molecule inhibitor of the TGFβ type I receptor kinase with IC50 of 59 nM. | ||
| M2081 | LY2109761 | TGF-β Receptor |
| LY2109761 is a novel TGF-β receptor type I and type II dual inhibitor. | ||
| M2108 | SB-525334 | TGF-β Receptor |
| SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 of 14.3 nM. | ||
| M2550 | SB-505124 | TGF-β Receptor |
| Sb-505124 is a selective inhibitor of TGF-βI receptor (ALK4, ALK5, ALK7) with IC50 values of 129 nM and 47 nM for ALK4 and ALK5, respectively. Sb-505124 also inhibits ALK7, but not ALK1, 2, 3 and 6. | ||
| M2610 | D4476 | Casein Kinase |
| Casein Kinase I Inhibitor | ||
| D4476 is a selective inhibitor of casein kinase 1 (CK1) and TGF-β type-I receptor (ALK5) with IC50 of 0.3 µM and 0.5 µM, respectively. | ||
| M5036 | A 77-01 | TGF-β Receptor |
| A 77-01 is a potent inhibitor of TGF-β type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM. | ||
| M5037 | A 83-01 | TGF-β Receptor |
| A83-01; A-83-01 | ||
| A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively).*The compound is unstable in solutions, freshly prepared is recommended | ||
| M5246 | EW-7197 | TGF-β Receptor |
| Vactosertib; TEW-7197 | ||
| EW-7197 is a highly potent, selective, and orally bioavailable TGF-β receptor ALK4/ALK5 inhibitor with IC50 of 13 nM and 11 nM, respectively. | ||
| M9222 | LY3200882 | TGF-β Receptor |
| LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC50 of 38.2 nM. LY3200882 is also used as an immune modulatory agent. | ||
| M9243 | ITD-1 | TGF-β Receptor |
| ITD-1 is a selective TGFβ receptor inhibitor with an IC50 of about 0.4-0.8 μM. | ||
| M14930 | Disitertide diammonium | TGF-beta/Smad |
| P144 diammonium | ||
| Disitertide (P144) diammonium is a polypeptide inhibitor of transforming growth factor TGFβ1, specifically blocking its interaction with the receptor. Disitertide diammonium was also an inhibitor of PI3K and an inducer of apoptosis. | ||
| M25343 | Sudubrilimab | PD-1/PD-L1 |
| HS636 | ||
| Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment. | ||
| M29038 | Isosaponarin | TGF-β Receptor |
| Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin increases collagen synthesis, caused by up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production. | ||
| M29975 | SB-505124 hydrochloride | TGF-β Receptor |
| SB-505124 hydrochloride is a selective inhibitor of TGF-β Receptor type I receptor (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6. | ||
| M54721 | A 83-01 sodium | TGF-beta/Smad |
| A 83-01 sodium is a potent inhibitor of TGF-β type I receptors ALK5, ALK4, and ALK7, inhibiting ALK5, ALK4, and ALK7-induced transcription with IC50 values of 12 nM, 45 nM, and 7.5 nM, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
